New trial results reveal ITM-11 significantly improves survival rates in GEP-NET patients, outperforming everolimus with better efficacy and safety profiles.
Jaume Capdevila, MD
Advertisement
Jaume Capdevila, MD, is a member of the Gastrointestinal and Endocrine Cancer Unit at Vall d'Hebron Hospital.
Articles by Jaume Capdevila, MD
Advertisement
Latest Updated Articles
Dr Capdevila on "Practice-Changing" COMPETE Trial in GEP-NETsPublished: October 31st 2025 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Alpelisib/Fulvestrant Improves PFS in Post-CDK4/6 HR+/HER2- Breast Cancer
2
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
3
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
4
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
5
